Tobias Goschzik
Overview
Explore the profile of Tobias Goschzik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
425
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sonksen M, Obrecht-Sturm D, Hernaiz Driever P, Sauerbrey A, Graf N, Kontny U, et al.
Neuro Oncol
. 2024 Jun;
26(11):2125-2139.
PMID: 38919026
Background: The outcome of children with medulloblastoma (MB) and Fanconi Anemia (FA), an inherited DNA repair deficiency, has not been described systematically. Treatment is complicated by high vulnerability to treatment-associated...
2.
Zschernack V, Thomas C, Schaub C, Kristiansen G, Waha A, Goschzik T, et al.
J Neuropathol Exp Neurol
. 2024 Jun;
83(10):887-889.
PMID: 38874462
No abstract available.
3.
Albrecht S, Miedzybrodzki B, Palma L, Nguyen V, Dudley R, Pietsch T, et al.
Free Neuropathol
. 2023 Jun;
3.
PMID: 37284158
Cowden syndrome (CS) is an autosomal dominant hamartoma and tumor predisposition syndrome caused by heterozygous pathogenic germline variants in in most affected individuals. Major features include macrocrania, multiple facial tricholemmomas,...
4.
Goddard J, Castle J, Southworth E, Fletcher A, Crosier S, Martin-Guerrero I, et al.
Acta Neuropathol
. 2023 Apr;
145(5):651-666.
PMID: 37014508
Group 4 tumours (MB) represent the majority of non-WNT/non-SHH medulloblastomas. Their clinical course is poorly predicted by current risk-factors. MB molecular substructures have been identified (e.g. subgroups/cytogenetics/mutations), however their inter-relationships...
5.
Tonn S, Korshunov A, Obrecht D, Sill M, Spohn M, von Hoff K, et al.
Neuro Oncol
. 2023 Jan;
25(8):1518-1529.
PMID: 36715306
Background: The prognostic impact of clinical risk factors and DNA methylation patterns in sonic hedgehog (SHH)-activated early childhood desmoplastic/nodular medulloblastoma (DMB) or medulloblastoma with extensive nodularity (MBEN) were evaluated to...
6.
Mynarek M, Obrecht D, Sill M, Sturm D, Kloth-Stachnau K, Selt F, et al.
Acta Neuropathol
. 2022 Dec;
145(1):97-112.
PMID: 36459208
Molecular groups of medulloblastoma (MB) are well established. Novel risk stratification parameters include Group 3/4 (non-WNT/non-SHH) methylation subgroups I-VIII or whole-chromosomal aberration (WCA) phenotypes. This study investigates the integration of...
7.
Goschzik T, Mynarek M, Doerner E, Schenk A, Spier I, Warmuth-Metz M, et al.
Acta Neuropathol
. 2022 Oct;
144(6):1143-1156.
PMID: 36181537
This study aimed to re-evaluate the prognostic impact of TP53 mutations and to identify specific chromosomal aberrations as possible prognostic markers in WNT-activated medulloblastoma (WNT-MB). In a cohort of 191...
8.
Niehusmann P, Stensvold E, Leske H, Pietsch T, Goschzik T, Gielen G, et al.
Pediatr Blood Cancer
. 2022 May;
69(9):e29736.
PMID: 35570402
Background: An unexplained regional difference in survival was observed in previous publications on outcome for children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor (CNS-PNET) in Norway. We aimed now...
9.
Goschzik T, Zur Muehlen A, Doerner E, Waha A, Friedrich C, Hau P, et al.
J Neuropathol Exp Neurol
. 2021 Apr;
80(5):419-430.
PMID: 33870422
Adult medulloblastomas (MB) are rare. We investigated the genetic landscape and prognostic impact of genetic aberrations in a cohort of 117 adult medulloblastomas. Histological features and pathway activation were evaluated...
10.
Goschzik T, Schwalbe E, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, et al.
Lancet Oncol
. 2018 Nov;
19(12):1602-1616.
PMID: 30392813
Background: Most children with medulloblastoma fall within the standard-risk clinical disease group defined by absence of high-risk features (metastatic disease, large-cell/anaplastic histology, and MYC amplification), which includes 50-60% of patients...